ASH 2024 | AE-free PFS benefit with first-line ibrutinib plus venetoclax for CLL: 64-month follow-up of GLOW

So the GLOW study is obviously treating patients with frailty, comorbidity or elderly patients with CLL, first-line treatment, same kind of population as we had in the CLL14 trial and same comparator being obinutuzumab chlorambucil, but here the experimental arm is ibrutinib-venetoclax. We’ve previously presented the progression-free survival and overall survival benefit that we have seen and will have longer follow up, there are sustainable benefits, improvements in terms of progression-free survival and overall survival. What we present this year as well is to focus on the toxicity together with the efficacy. Thus, we use what’s considered toxicity-free, progression-free survival as an outcome. Toxicity here defined as grade 3 or above adverse events and we monitor the time where the patient might have toxicity and subtract that from the progression-free survival because we have so many good options for treatment today in CLL and we need to assess not just efficacy but also quality of life and this is another way of assessing that. And doing that we see that patients treated with ibrutinib venetoclax gain more than 20 months toxicity-free progression-free survival as compared to patients treated with chlorambucil obinutuzumab. So despite the longer treatment period, a little more than a year as compared to less than half a year with chlorambucil obinutuzumab, the patients still have a much better toxicity-free, progression-free survival.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.